Eisai Launches Its First Drug In Russia, A Breast-Cancer Treatment
This article was originally published in PharmAsia News
Executive Summary
Eisai said it has launched its first drug in Russia, its Halaven (eribulin) breast-cancer drug, already approved in 50 other countries.